The interrelationships of the gut microbiome and inflammation in colorectal carcinogenesis

Clinics in Laboratory Medicine

Volumn 34, Issue 4, 2014, Pages 699-710

  Cho, Margaret ^a   Carter, Janell ^a   Harari, Saul ^a   Pei, Zhiheng ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Carcinogenesis; Colorectal cancer; Gut microbiome; Inflammation

Indexed keywords

PROBIOTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BACTEROIDES FRAGILIS; CARCINOGENESIS; CHRONIC INFLAMMATION; COLON CARCINOGENESIS; COLORECTAL CANCER; COLORECTAL CARCINOGENESIS; CROHN DISEASE; DISEASE ASSOCIATION; EXPERIMENTAL INFLAMMATORY BOWEL DISEASE; FUSOBACTERIUM; HUMAN; INFLAMMATION; INTESTINE FLORA; MICROBIOME; NONHUMAN; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS EQUINUS; ULCERATIVE COLITIS; COLON; COLORECTAL NEOPLASMS; GENETIC PREDISPOSITION; MICROBIOLOGY; MICROFLORA; PATHOLOGY; TUMOR MICROENVIRONMENT;

CARCINOGENESIS; COLON; COLORECTAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICROBIOTA; PROBIOTICS; TUMOR MICROENVIRONMENT;

EID: 84923916886     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2014.08.002     Document Type: Review

References (86)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
3. Kohler B.A., Ward E., McCarthy B.J., et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. JNatl Cancer Inst 2011, 103(9):714-736.
4. Eddy D.M. Screening for colorectal cancer. Ann Intern Med 1990, 113(5):373-384.
5. Burt R.W., DiSario J.A., Cannon-Albright L. Genetics of colon cancer: impact of inheritance on colon cancer risk. Annu Rev Med 1995, 46:371-379.
6. Lynch H.T., Smyrk T.C., Watson P., et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 1993, 104(5):1535-1549.
7. Domingo E., Niessen R.C., Oliveira C., et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene 2005, 24(24):3995-3998.
8. Atkin W.S., Morson B.C., Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. NEngl J Med 1992, 326(10):658-662.
9. Imperiale T.F., Ransohoff D.F. Risk for colorectal cancer in persons with a family history of adenomatous polyps: a systematic review. Ann Intern Med 2012, 156(10):703-709.
10. Potter J.D. Colorectal cancer: molecules and populations. JNatl Cancer Inst 1999, 91(11):916-932.
11. Glei M., Latunde-Dada G.O., Klinder A., et al. Iron-overload induces oxidative DNA damage in the human colon carcinoma cell line HT29 clone 19A. Mutat Res 2002, 519(1-2):151-161.
12. Samowitz W.S., Albertsen H., Sweeney C., et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. JNatl Cancer Inst 2006, 98(23):1731-1738.
13. Fearon E.R., Vogelstein B. Agenetic model for colorectal tumorigenesis. Cell 1990, 61(5):759-767.
14. Weisenberger D.J., Siegmund K.D., Campan M., et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006, 38(7):787-793.
15. Vogelstein B., Fearon E.R., Hamilton S.R., et al. Genetic alterations during colorectal-tumor development. NEngl J Med 1988, 319(9):525-532.
16. Burmer G.C., Levine D.S., Kulander B.G., et al. c-Ki-ras mutations in chronic ulcerative colitis and sporadic colon carcinoma. Gastroenterology 1990, 99(2):416-420.
17. Itzkowitz S.H. Inflammatory bowel disease and cancer. Gastroenterol Clin North Am 1997, 26(1):129-139.
18. Chan A.T., Giovannucci E.L. Primary prevention of colorectal cancer. Gastroenterology 2010, 138(6):2029-2043.
19. Bingham S.A. Epidemiology and mechanisms relating diet to risk of colorectal cancer. Nutr Res Rev 1996, 9(1):197-239.
20. McIllmurray M.B., Langman M.J. Large bowel cancer: causation and management. Gut 1975, 16(10):815-820.
21. Arthur J.C., Jobin C. The complex interplay between inflammation, the microbiota and colorectal cancer. Gut Microbes 2013, 4(3):253-258.
22. Sobhani I., Amiot A., Le Baleur Y., et al. Microbial dysbiosis and colon carcinogenesis: could colon cancer be considered a bacteria-related disease?. Therap Adv Gastroenterol 2013, 6(3):215-229.
23. Savage D.C. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol 1977, 31:107-133.
24. Zhu Q., Gao R., Wu W., et al. The role of gut microbiota in the pathogenesis of colorectal cancer. Tumour Biol 2013, 34(3):1285-1300.
25. Tlaskalová-Hogenová H., Stepánková R., Hudcovic T., et al. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett 2004, 93(2-3):97-108.
26. Mai V. Dietary modification of the intestinal microbiota. Nutr Rev 2004, 62(6 Pt 1):235-242.
27. Stanghellini V., Barbara G., Cremon C., et al. Gut microbiota and related diseases: clinical features. Intern Emerg Med 2010, 5(Suppl 1):S57-S63.
28. Gold J.S., Bayar S., Salem R.R. Association of Streptococcus bovis bacteremia with colonic neoplasia and extracolonic malignancy. Arch Surg 2004, 139(7):760-765.
29. Moore W.E., Moore L.H. Intestinal floras of populations that have a high risk of colon cancer. Appl Environ Microbiol 1995, 61(9):3202-3207.
30. Nakamura J., Kubota Y., Miyaoka M., et al. Comparison of 4 microbial enzymes in Clostridia and Bacteroides isolated from human feces. Microbiol Immunol 2002, 46(7):487-490.
31. McIntosh G.H., Royle P.J., Playne M.J. Aprobiotic strain of L. acidophilus reduces DMH-induced large intestinal tumors in male Sprague-Dawley rats. Nutr Cancer 1999, 35(2):153-159.
32. Rowland I.R., Bearne C.A., Fischer R., et al. The effect of lactulose on DNA damage induced by DMH in the colon of human flora-associated rats. Nutr Cancer 1996, 26(1):37-47.
33. Cuevas-Ramos G., Petit C.R., Marcq I., et al. Escherichia coli induces DNA damage invivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci USA 2010, 107(25):11537-11542.
34. Chen W., Liu F., Ling Z., et al. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS One 2012, 7(6):e39743.
35. Gueimonde M., Ouwehand A., Huhtinen H., et al. Qualitative and quantitative analyses of the bifidobacterial microbiota in the colonic mucosa of patients with colorectal cancer, diverticulitis and inflammatory bowel disease. World J Gastroenterol 2007, 13(29):3985-3989.
36. Shen X.J., Rawls J.F., Randall T., et al. Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. Gut Microbes 2010, 1(3):138-147.
37. Sobhani I., Tap J., Roudot-Thoraval F., et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One 2011, 6(1):e16393.
38. Signat B., Roques C., Poulet P., et al. Fusobacterium nucleatum in periodontal health and disease. Curr Issues Mol Biol 2011, 13(2):25-36.
39. Kostic A.D., Gevers D., Pedamallu C.S., et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012, 22(2):292-298.
40. Castellarin M., Warren R.L., Freeman J.D., et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012, 22(2):299-306.
41. Ahn J., Sinha R., Pei Z., et al. Human gut microbiome and risk for colorectal cancer. JNatl Cancer Inst 2013, 105(24):1907-1911.
42. Flanagan L., Schmid J., Ebert M., et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis 2014, 33(8):1381-1390.
43. McCoy A.N., Araújo-Pérez F., Azcárate-Peril A., et al. Fusobacterium is associated with colorectal adenomas. PLoS One 2013, 8(1):e53653.
44. Tahara T., Yamamoto E., Suzuki H., et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res 2014, 74(5):1311-1318.
45. Rubinstein M.R., Wang X., Liu W., et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 2013, 14(2):195-206.
46. Reddy B.S., Mastromarino A., Wynder E.L. Further leads on metabolic epidemiology of large bowel cancer. Cancer Res 1975, 35(11 Pt 2):3403-3406.
47. Ellmerich S., Djouder N., Schöller M., et al. Production of cytokines by monocytes, epithelial and endothelial cells activated by Streptococcus bovis. Cytokines 2000, 12(1):26-31.
48. Rowland I.R. The role of the gastrointestinal microbiota in colorectal cancer. Curr Pharm Des 2009, 15(13):1524-1527.
49. Gill C.I., Rowland I.R. Diet and cancer: assessing the risk. Br J Nutr 2002, 88(Suppl 1):S73-S87.
50. de Giorgio R., Blandizzi C. Targeting enteric neuroplasticity: diet and bugs as new key factors. Gastroenterology 2010, 138(5):1663-1666.
51. Rubin D.C., Shaker A., Levin M.S. Chronic intestinal inflammation: inflammatorybowel disease and colitis-associated colon cancer. Front Immunol 2012, 3:107.
52. Powolny A., Xu J., Loo G. Deoxycholate induces DNA damage and apoptosis in human colon epithelial cells expressing either mutant or wild-type p53. Int J Biochem Cell Biol 2001, 33(2):193-203.
53. Narahara H., Tatsuta M., Iishi H., et al. K-ras point mutation is associated with enhancement by deoxycholic acid of colon carcinogenesis induced by azoxymethane, but not with its attenuation by all-trans-retinoic acid. Int J Cancer 2000, 88(2):157-161.
54. Radley S., Davis A.E., Imray C.H., et al. Biliary bile acid profiles in familial adenomatous polyposis. Br J Surg 1992, 79(1):89-90.
55. Nougayrède J.P., Homburg S., Taieb F., et al. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 2006, 313(5788):848-851.
56. Hope M.E., Hold G.L., Kain R., et al. Sporadic colorectal cancer-role of the commensal microbiota. FEMS Microbiol Lett 2005, 244(1):1-7.
57. Rhee K.J., Wu S., Wu X., et al. Induction of persistent colitis by a human commensal, enterotoxigenic Bacteroides fragilis, in wild-type C57BL/6 mice. Infect Immun 2009, 77(4):1708-1718.
58. Wu S., Morin P.J., Maouyo D., et al. Bacteroides fragilis enterotoxin induces c-Myc expression and cellular proliferation. Gastroenterology 2003, 124(2):392-400.
59. Wu S., Rhee K.J., Albesiano E., et al. Ahuman colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009, 15(9):1016-1022.
60. Wang L., Yi T., Kortylewski M., et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. JExp Med 2009, 206(7):1457-1464.
61. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441(7092):431-436.
62. Yu H., Kortylewski M., Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007, 7(1):41-51.
63. Moossavi S., Bishehsari F. Inflammation in sporadic colorectal cancer. Arch Iran Med 2012, 15(3):166-170.
64. Uronis J.M., Mühlbauer M., Herfarth H.H., et al. Modulation of the intestinal microbiota alters colitis associated colorectal cancer susceptibility. PLoS One 2009, 4(6):e6026.
65. Neufert C., Becker C., Neurath M.F. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc 2007, 2:1998-2004.
66. Ivanov I.I., Frutos Rde L., Manel N., et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 2008, 4:337-349.
67. Mazmanian S.K., Round J.L., Kasper D.L. Amicrobial symbiosis factor prevents intestinal inflammatory disease. Nature 2008, 453(7195):620-625.
68. Sheehan K.M., Sheahan K., O'Donoghue D.P., et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999, 282(13):1254-1257.
69. Arber N., Eagle C.J., Spicak J., et al. Celecoxib for the prevention of colorectal adenomatous polyps. NEngl J Med 2006, 355(9):885-895.
70. Taketo M.M. COX-2 and colon cancer. Inflamm Res 1998, 47(Suppl 2):S112-S116.
71. Pugh S., Thomas G.A. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut 1994, 35(5):675-678.
72. Yang V.W., Shields J.M., Hamilton S.R., et al. Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res 1998, 58(8):1750-1753.
73. Kawamori T., Uchiya N., Sugimura T., et al. Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 2003, 24(5):985-990.
74. Castellone M.D., Teramoto H., Williams B.O., et al. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005, 310(5753):1504-1510.
75. Tessner T.G., Muhale F., Riehl T.E., et al. Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation. JClin Invest 2004, 114(11):1676-1685.
76. Pozzi A., Yan X., Macias-Perez I., et al. Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. JBiol Chem 2004, 279(28):29797-29804.
77. Tsujii M., Kawano S., DuBois R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997, 94(7):3336-3340.
78. Zhu Y., Michelle Luo T., Jobin C., et al. Gut microbiota and probiotics in colon tumorigenesis. Cancer Lett 2011, 309(2):119-127.
79. Pala V., Sieri S., Berrino F., et al. Yogurt consumption and risk of colorectal cancer in the Italian European prospective investigation into cancer and nutrition cohort. Int J Cancer 2011, 129(11):2712-2719.
80. de Vrese M., Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv Biochem Eng Biotechnol 2008, 111:1-66.
81. Arumugam M., Raes J., Pelletier E., et al. Enterotypes of the human gut microbiome. Nature 2011, 473(7346):174-180.
82. Corthésy B., Gaskins H.R., Mercenier A. Cross-talk between probiotic bacteria and the host immune system. JNutr 2007, 137(3 Suppl 2):781S-790S.
83. Orlando A., Messa C., Linsalata M., et al. Effects of Lactobacillus rhamnosus GG on proliferation and polyamine metabolism in HGC-27 human gastric and DLD-1 colonic cancer cell lines. Immunopharmacol Immunotoxicol 2009, 31(1):108-116.
84. Lee N.K., Park J.S., Park E., et al. Adherence and anticarcinogenic effects of Bacillus polyfermenticus SCD in the large intestine. Lett Appl Microbiol 2007, 44(3):274-278.
85. Kim Y., Lee D., Kim D., et al. Inhibition of proliferation in colon cancer cell lines and harmful enzyme activity of colon bacteria by Bifidobacterium adolescentis SPM0212. Arch Pharm Res 2008, 31(4):468-473.
86. Tlaskalová-Hogenová H., Stěpánková R., Kozáková H., et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 2011, 8(2):110-120.